Global Hereditary Orotic Aciduria Market, By Drug Type (Cytidine monophosphate and Uridine monophosphate), By Indication (Type 1 and Type 2), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), By Geography (North Amer

Global Hereditary Orotic Aciduria Market, By Drug Type (Cytidine monophosphate and Uridine monophosphate), By Indication (Type 1 and Type 2), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

Global hereditary orotic aciduria market was valued at US$ 357.9 Mn in 2023 and is expected to reach US$ 509.8 Mn by 2031, exhibiting at a compound annual growth rate (CAGR) of 4.5% from 2024 to 2031.

Figure 1. Global Hereditary Orotic Aciduria Market Share (%), By Region, 2024

Hereditary orotic aciduria (HOA) is a very rare inborn error of pyrimidine metabolism. It results from a defect of the uridine-5-monophosphate synthase (UMPS) gene. Hereditary orotic aciduria is an extremely rare genetic disorder. When untreated, affected infants can develop a blood (hematologic) disorder called megaloblastic anemia as well as failure to thrive, susceptibility to infection, and orotic acid crystals in the urine (crystalluria), resulting from excretion of orotic acid in the urine. Since, very few individuals have been identified with this disorder, not much is known of hereditary orotic aciduria. It is the only known as the enzyme deficiency of the pyrimidine biosynthetic pathway, resulting from a deficiency in one or both of the activities of the bifunctional enzyme uridine-5-monophosphate synthase (UMPS). The presumed cause of HOA is biallelic missense mutations resulting in decreased levels of the enzyme and impaired substrate binding. UMPS defects lead to the accumulation of orotate (OA) and/or of orotidine monophosphate (OMP), which eventually getsexcreted in the urine. The hallmarks of the disease are a megaloblastic bone marrow that is refractory to hematinic therapy, accompanied by a markedly increased excretion of orotic acid in the urine.

Market Dynamics:

Increasing government initiatives for rare diseases is expected to drive the growth of the market over the forecast period. For instance, in March 2021, the government of India has launched National Policy for Rare Diseases (NPRD) for the treatment of rare disease patients. The salient features of NPRD, 2021 are as under: The rare diseases have been identified and categorized into 3 groups namely Group 1, Group 2 and Group 3.

• Group 1: Disorders amenable to one-time curative treatment.
• Group-2: Diseases requiring long term/lifelong treatment having relatively lower cost of treatment and benefit has been documented in literature and annual or more frequent surveillance is required.
• Group 3: Diseases for which definitive treatment is available but challenges are to make optimal patient selection for benefit, very high cost, and lifelong therapy.

Key features of the study:

• This report provides an in-depth analysis of the global hereditary orotic aciduria market, and provides market size (US$ Mn) and compound annual growth rate (CAGR %) for the forecast period (2024-2031), considering 2023 as the base year.
• It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market.
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players.
• It profiles key players in the global hereditary orotic aciduria market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies.
• Key companies covered as a part of this study include Merck & Co. Inc and SERB Pharmaceuticals.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
• Global hereditary orotic aciduria market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global hereditary orotic aciduria market.

Detailed Segmentation:

• Global Hereditary Orotic Aciduria Market, By Drug Type
• Cytidine monophosphate
• Uridine monophosphate
• Global Hereditary Orotic Aciduria Market, By Indication
• Type 1
• Type 2
• Global Hereditary Orotic Aciduria Market, By Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Global Hereditary Orotic Aciduria Market, By Region
• North America
• Europe
• Asia Pacific
• Latin America
• Middle East
• Africa
• Top Companies in the Global Hereditary Orotic Aciduria Market:
• Merck & Co. Inc
• SERB Pharmaceuticals